Article Information
History
- August 10, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Ronja Hietikko1,2,*,
- Tuomas Mirtti2,3,
- Tuomas P. Kilpeläinen1,2,
- Teemu Tolonen4,
- Anne Räisänen-Sokolowski3,5,
- Stig Nordling2,
- Jill Hannus4,
- Marita Laurila4,
- Kimmo Taari1,
- Teuvo LJ Tammela6,
- Reija Autio7,
- Kari Natunen7,
- Anssi Auvinen7 and
- Antti Rannikko1,2
- 1Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
- 2Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
- 3HUS Diagnostic Center, Department of Pathology, HUS Helsinki University Hospital, Helsinki, Finland
- 4Fimlab Laboratories, Department of Pathology, Tampere University Hospital, Tampere, Finland
- 5Department of Pathology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
- 6Department of Urology, Tampere University Hospital, Tampere, Finland
- 7Faculty of Social Sciences, Tampere University, Tampere, Finland
- ↵*Corresponding author; email: ronja.hietikko{at}icloud.com
Posted August 10, 2023.
Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study
